|
IQVIA™ Real-World Insights Bibliography
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
|
| Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens
Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore,
Aida Aydemir, Irene Bezemer & Meritxell Sabidó
|
| Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia;
b The Alfred Hospital, Melbourne, VIC, Australia;
c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland;
e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany;
f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland;
g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland;
h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway;
i Department of Clinical Medicine, University of Bergen, Bergen, Norway;
j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France;
m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA;
n Global Epidemiology, IQVIA, Amsterdam, The Netherlands;
o Merck Healthcare KGaA, Darmstadt, Germany"
|
| Publication(s): |
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Population Based Study, |
|
 |
| |
| |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets |
| Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group |
| Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
2The Alfred Hospital, Melbourne, Australia.
3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France.
4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).
5Global Database Studies, IQVIA, Tartu, Estonia.
6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands.
7IQVIA (former EPID Research), Espoo, Finland.
8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. |
Publication(s): Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
|
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Drug safety, Neurological disorders,
2022 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. |
| Author(s): Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. |
| Affiliations(s): 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.
2Centre for Observational Research, Amgen Ltd, Uxbridge, UK.
3IMS Health Sweden, Stockholm, Sweden.
|
Publication(s): Clinical Epidemiology
|
| Document Type(s): Article, |
| Countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, |
| Click here for the abstract |
C:
Y: |
Oncology,
2016 |
|
L:
A: |
English
Literature Review, |
|
|
| |
| |
| Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. |
| Author(s): Peyrin-Biroulet L1, Van Assche G2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. |
| Affiliations(s): 1Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
2Division of Gastroenterology, University Hospitals Leuven, Leuven Belgium.
3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany.
4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom.
6Gastroenterology Practice, Minden, Germany.
7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom.
10IMS Health, Real World Evidence Solutions, Spain.
11Merck & Co., Inc., Kenilworth, NJ, United States
|
Publication(s):
Dig Liver Dis. 2016 Jun;48(6):601-7.
|
| Document Type(s): Article, |
| Countries: Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK, |
C:
Y: |
Gastrointestinal disorders,
2016 |
|
L:
A: |
English
Burden of illness, Patient questionnaire, Survey research, |
|
|
| |
| |
| Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study |
| Author(s): Van Assche G1, Peyrin-Biroulet L2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. |
| Affiliations(s): 1Division of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. Electronic address: gert.vanassche@uzleuven.be.
2Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.
3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany.
4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica and Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK.
6Gastroenterology Practice, Minden, Germany.
7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.
10IMS Health, Real World Evidence Solutions, Barcelona, Spain.
11Merck & Co., Inc., Rahway, NJ, United States.
|
Publication(s): Dig Liver Dis. 2016 Jun;48(6):592-600
|
| Document Type(s): Article, |
| Countries: Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK, |
C:
Y: |
Gastrointestinal disorders,
2016 |
|
L:
A: |
English
Burden of illness, Patient questionnaire, |
|
|
| |
| |
| Management of cardiovascular risk factors for primary prevention: evaluation of Turkey results of the EURIKA study. |
| Author(s): Abaci A1. |
| Affiliations(s): 1Department of Cardiology, Medicine Faculty of Gazi University, Ankara, Turkey |
Publication(s): Turk Kardiyol Dern Ars. 2012 Mar;40(2):135-42. doi: 10.5543/tkda.2012.01827.
|
| Document Type(s): Article, |
| Countries: Turkey, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2012 |
|
L:
A: |
English
Prospective study, |
|
|
| |
| |
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. |
| Author(s): Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7,
Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10,
Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 |
| Affiliations(s): 1
Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2
CIBER of
Epidemiology and Public Health, Madrid, Spain; 3
Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4
Department of Epidemiology, Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD 21205, USA; 5
Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6
Welch Center for
Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7
Department of Cardiovascular Epidemiology and
Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8
Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN,
UK; 9
Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003
Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium |
Publication(s): Eur Heart J. 2011 Sep;32(17):2143-52
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2011 |
|
L:
A: |
English
Observational study, Prospective study, |
|
|
| |
| |
| Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. |
| Author(s): Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F. |
| Affiliations(s): |
Publication(s): BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704.
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2011 |
|
L:
A: |
English
Observational study, Prospective study, |
|
|
| |
| |
| Poor asthma control defined by a derived ACITM score is associated with increased unscheduled healthcare resource use in Turkey |
| Author(s): Gemicioglu B1, Williams AE2, Lloyd AC3, Sekerel B4. |
| Affiliations(s): 1 Istanbul University Faculty of Medicine Cerrahpasa, Turkey 2 Global Health Outcomes, GlaxoSmithKline R&D, UK 3 IMS Health inc. Fourth Hurdle Consulting Ltd, London, UK 4 Hacettepe University Faculty of Medicine, Pediatric Allergy and Asthma Unit, Ankara, Turkey |
Publication(s): European Respiratory Society, Munich, 2006
|
| Document Type(s): Poster, |
| Countries: Turkey, |
C:
Y: |
Respiratory disease,
2006 |
|
L:
A: |
English
Cost of illness, |
|
|
| |
| |
| A derived Asthma Control TestTM (ACT) score indicates poor asthma control with increased unscheduled healthcare resource use (UnHCRU) in Turkey. |
| Author(s): Gemicioglu B1, Williams AE2, Lloyd AC3, Sekerel B4. |
| Affiliations(s): 1 Istanbul University Faculty of Medicine Cerrahpasa, Turkey 2 Global Health Outcomes, GlaxoSmithKline R&D, UK 3 Fourth Hurdle Consulting Ltd, London, UK 4 Hacettepe University Faculty of Medicine, Pediatric Allergy and Asthma Unit, Ankara, Turkey |
Publication(s): 9th Annual Congress of Turkish Thoracic Societ Kemer, April 2006
|
| Document Type(s): Oral presentation, |
| Countries: Turkey, |
C:
Y: |
Respiratory disease,
2006 |
|
L:
A: |
English
Quality of life, |
|
|
| |
| |
|
|
|
